u-blox Aktie 3336167 / CH0033361673
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
30.10.2025 07:38:44
|
Provisional end result of public tender offer for u-blox
|
u-blox AG / Key word(s): Tender Offer Thalwil, Switzerland, and Luxembourg, 30 October 2025 – ZI Zenith S.à r.l. (“Zenith”), a European indirect subsidiary of funds managed and/or advised by Advent International, L.P. (“Advent”), a leading private equity investor, today announced the provisional notice of the end result of its public tender offer (“Offer”) for all publicly held registered shares of u-blox Holding AG (“u-blox”) (SIX: UBXN), a global provider of positioning and wireless communication technologies. As of the end of the additional acceptance period on 29 October 2025, based on preliminary figures, 6,980,689 u-blox shares have been tendered. Taking into account the shares already held by Zenith and persons acting in concert with it, Zenith’s total participation amounts to 7,294,181 u-blox shares, corresponding to 94.36% of the issued share capital and voting rights of u-blox. The provisional notice of the end result has been published on the official publication platform of the Swiss Takeover Board and is available at www.zenith-offer.com. The definitive notice of the end result will be published on 4 November 2025. Completion of the transaction is expected in the fourth quarter of 2025, subject to the fulfillment of the offer conditions and receipt of required regulatory approvals. Following settlement of the Offer and subject to these conditions, Advent intends to initiate a squeeze-out procedure and to delist u-blox shares from the SIX Swiss Exchange. At the extraordinary general meeting held on 28 October 2025, shareholders approved all proposed resolutions, including the delisting of u-blox shares from the SIX Swiss Exchange and the election of the new members of the Board of Directors. Claudio Simão was elected as member and Chairman of the Board of Directors. Ronald Ayles and Bernhard Spetsmann were elected as members of the Board of Directors. In addition, Claudio Simão and Ronald Ayles were elected as members of the company’s Nomination, Compensation and Sustainability Committee. All elections are subject to, and will become effective upon, completion of the public tender offer. Ends For further information, please contact:
About u-blox About Advent
End of Inside Information |
| Language: | English |
| Company: | u-blox AG |
| Zürcherstrasse 68 | |
| 8800 Thalwil | |
| Switzerland | |
| Phone: | +41 44 722 74 44 |
| Fax: | +41 44 722 74 47 |
| E-mail: | ir@u-blox.com |
| Internet: | www.u-blox.com |
| ISIN: | CH0033361673 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2220880 |
| End of Announcement | EQS News Service |
|
|
2220880 30-Oct-2025 CET/CEST
Nachrichten zu u-blox AG
|
12:29 |
u-blox Aktie News: u-blox zeigt sich am Mittag fester (finanzen.ch) | |
|
09:29 |
u-blox Aktie News: u-blox am Vormittag freundlich (finanzen.ch) | |
|
07:57 |
U-Blox-Übernahme: Advent hält nun über 94 Prozent der Aktien (AWP) | |
|
07:38 |
Provisional end result of public tender offer for u-blox (EQS Group) | |
|
07:18 |
Changes in u-blox’s Executive Committee (EQS Group) | |
|
29.10.25 |
u-blox-Aktie etwas fester: Aktionäre stimmen Delisting von der Schweizer Börse zu (AWP) |
Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall
Im BX Morning Call spricht die Schweizer Unternehmer-Ikone Etienne Jornod (OM Pharma) mit François Bloch und Olivia Hähnel (BX Swiss) über Führung, Wachstum, Kooperationen, seine Zeit bei der NZZ und darüber, warum Zuhören der wichtigste Leadership-Skill ist.
Die perfekte Folge für alle, die sich für Pharmastrategien, Galenica/Vifor und Unternehmertum interessieren.
🎯 Themen im Interview mit Etienne Jornod (OM Pharma)
– Antrieb und Führungsphilosophie eines Unternehmers
– Erfolgsweg von Galenica – Lehren aus Jahrzehnten Führung
– Frauenquote, Teamkultur und Leadership bei OM Pharma
– Internationale Expansion: China, USA und neue Märkte
– Forschung, Druck und Verantwortung in der Pharmaindustrie
– Inspiration, Balance und persönliche Haltung zum Erfolg
– Zukunftsvisionen: Schweiz, Unternehmertum und Investments
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach EZB-Zinsentscheid: SMI und DAX letztlich wenig bewegt -- Wall Street schliessen tiefer -- Märkte in Fernost zum Handelsende uneinsAm heimischen sowie am deutschen Aktienmarkt hielten sich Anleger zurück. An der Wall Street ging es nach unten. Die wichtigsten asiatischen Börsen wiesen am Donnerstag verschiedene Vorzeichen aus.


